📈 Price History

Ratio Health

— Excellent

— Good

— Average

— Poor

By Category

📊 Peer Medians

About

BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company’s products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; and KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease. The company’s products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy. It serves specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers. The company has license and collaboration agreements with and Ares Trading S.A. The company was incorporated in 1996 and is based in San Rafael, California.

Key Ratios Snapshot

📈 Growth Pattern

⚡ Latest Quarter —

See full financials →

📊 Quick Scorecard

Loading…

⭐ Superinvestors Holding BMRN

View All Superinvestors →

Manager	Shares	Value	% of Fund	Period
Andreas Halvorsen Viking Global Investors	7.06M	$398.9M	1.12%	Mar 2026
Steve Cohen Point72 Asset Management	1.20M	$67.7M	0.09%	Mar 2026
Jim Simons Renaissance Technologies LLC	1.02M	$57.9M	0.09%	Mar 2026

SEC Form 13F data. 45-day lag from quarter end.

🔍 Concall Decoded

🎙 Management Tone Tracker Confident Specific → Stable 4 quarters analysed

Q2 2025

Confident Specific

Management repeatedly used phrases like 'very pleased with our Q2 performance', 'double-digit year-over-year revenue growth', 'excited to share', and provided concrete numeric guidance targets (e.g., VOXZOGO $900M-$935M, non-GAAP EPS $4.40-$4.55). The tone is assertive and data-driven.

Q3 2025

Confident Specific

Management repeatedly used phrases like 'very pleased with the strong results', 'raised full-year total revenues guidance at the midpoint', and 'reaffirm our VOXZOGO revenue outlook'. They provided specific numbers for raised guidance, VOXZOGO range, and cash position. However, they were cautious on 2027 outlook, offering only a wide range rather than a narrow target.

Q4 2025

Confident Specific

Management used definitive language like 'outstanding growth', 'record revenues', and provided specific numerical guidance ranges for 2026, while directly addressing competitive dynamics with data-backed rebuttals.

Q1 2026 latest

Confident Specific

Management consistently uses forward-looking phrases like 'momentous year', 'strengthening trajectory', 'robust growth', and 'strong patient demand' throughout prepared remarks. They project specific revenue growth percentages (20% total, ~30% enzyme therapies) and detail integration plans, indicating a confident and concrete outlook.

Guidance Reliability Pending · <3Q data

Investor Lens

The investment thesis is strengthened after this call. The completion of the Amicus acquisition provides immediate revenue diversification and a clear growth catalyst (20% increase in 2026 revenue guidance). The strong underlying patient demand for Voxzogo and Palynziq, combined with the under-2 cohort momentum, supports the core business. Two pivotal readouts in Q2 (hypochondroplasia and BMN 401) offer upside optionality. The key risk to watch is the ITC decision in August/December regarding Ascendis's IP challenge, which could impact Voxzogo. Next quarter's update on Amicus peak revenue potential and synergy targets will be critical to refining the long-term margin trajectory. Overall, the narrative has shifted from a single-product story to a multi-product growth platform with near-term catalysts.

AI-generated concall tone analysis · Updated 2026-06-08 · Not investment advice

📐

3-Statement Financial Model

Bear / Base / Bull projections · DCF fair value · Reverse-DCF

Open Model →

🎙 Management Tone Confident Specific → Stable 4 quarters Full tone analysis in Intelligence →

📊 MIXED BioMarin completes Amicus acquisition, lifts 2026 revenue growth to 20% with Galafold and Pombiliti.

Revenue & Profitability

Q1 total revenues were $766 million. Full-year 2026 revenue guidance raised to $3.825-3.925 billion (20% YoY growth at midpoint), including enzyme therapies guidance of $2.725-2.775 billion (30% growth at midpoint). Voxzogo guidance maintained at $975-1025 million. Non-GAAP diluted EPS guidance is $4.85-5.05. Q1 non-GAAP diluted EPS was $0.76, impacted by a $31 million manufacturing charge and pre-close Amicus costs. Over 55% of revenues expected in H2 2026.

Outlook

Management sees strong demand for rare disease therapies, particularly from younger patient populations and earlier diagnosis. The company noted encouraging early momentum from Palynziq's adolescent label expansion and increasing diagnosis rates for hypochondroplasia. Geopolitical uncertainties in the Middle East are being monitored, and guidance includes a modest allowance for disruption.

Growth Drivers

Key growth levers include: (1) Amicus integration, with Galafold driven by undiagnosed Fabry patients and Pombiliti/Opfolda driven by switching from existing Pompe therapies; (2) Palynziq's U.S. adolescent launch and expected European approval; (3) Voxzogo continued penetration in under-2-year-olds (over half of new starts in Q1) and upcoming hypochondroplasia approval; (4) pipeline catalysts including BMN 401 and BMN 333. The company expects high-teens to low-20s% organic growth for Amicus products in 2026.

Balance Sheet & CapEx

Not discussed in this earnings call.

Margins

Not discussed in detail on this call. Non-GAAP diluted EPS guidance implies margin expectations. The Amicus acquisition is expected to be slightly dilutive to EPS in full-year 2026, accretive in the first 12 months post-close, and substantially accretive beginning in 2027. Q1 margins were impacted by a $31 million manufacturing charge and pre-close costs.

Key Risks

Management flagged order timing dynamics, which caused Q1 revenue fluctuations. Geopolitical uncertainties in the Middle East could impact operations. The ITC outcome with Ascendis is a near-term risk. Execution risk in integrating Amicus and achieving synergy targets. Competition in achondroplasia and reliance on pipeline data readouts (hypochondroplasia, ENPP1 deficiency) are also noted.

Generated by AI · Q1 2026 results · Not investment advice

✓ 📞 Earnings Call Transcripts (5 quarters) submit a missing quarter

🔍

🔎 See cross-company document search → ?

📞 Earnings Call Transcripts (5)

Q2 2026 Q2 2026 2026-08-06

Q2 revenue grew 20% year-over-year to nearly $1 billion, driven by strong commercial execution and the successful Amicus integration. Raised full-year guidance for revenue and EPS, with VOXZOGO, GALAFOLD, and POMBILITI/OPFOLDA all on track for blockbuster status. Integration synergies and pipeline progress support a robust outlook.

Q1 2026 Q1 2026 2026-05-04

Amicus acquisition completed, boosting 2026 revenue growth outlook to 20% and expanding the commercial portfolio with Galafold and Pombiliti/Opfolda. Q1 revenues rose to $766M, driven by enzyme therapies and Voxzogo, with strong patient demand and new launches supporting future growth.

Q4 2025 Q4 2025 2026-02-23

2025 saw 13% revenue growth to $3.22B, led by enzyme therapies and Voxzogo, with strong global expansion and profitability. 2026 guidance projects continued high single-digit growth, new product launches, and integration of Amicus assets, with a focus on innovation and operational efficiency.

Q3 2025 Q3 2025 2025-10-27

Raised 2025 revenue guidance and reaffirmed VOXZOGO outlook amid 11% YTD growth and strong cash flow. Divestment of ROCTAVIAN and a $221M IPR&D charge mark portfolio shifts, while 2027 revenue scenarios reflect competitive uncertainties.

Q2 2025 Q2 2025 2025-08-04

Q2 2025 saw double-digit revenue and profit growth, driven by strong global demand and new patient starts. Full-year guidance for revenue, margin, and EPS was raised, with VOXZOGO and enzyme therapies leading performance. Pipeline progress and the Inozyme acquisition further support long-term growth.

📊 Analysis Methodology

This comprehensive investment analysis was conducted using The Finmagine™ Stock Analysis & Ranking Methodology, a proprietary framework that systematically evaluates stocks across five critical dimensions: Financial Health, Growth Prospects, Competitive Positioning, Management Quality, and Valuation.

🎯

Discover Our Proven Investment Framework Learn how we analyze and rank stocks using advanced quantitative models, multi-dimensional scoring systems, and dynamic discriminatory ranking techniques that have guided successful investment decisions across market cycles.

📊 Explore The Finmagine™ Methodology

A comprehensive, bias-free framework for analyzing and ranking stocks by Financial Strength, Growth Potential, Competitive Edge, Management Quality, and Value.

⚠️ Important Disclaimers — Please read without fail.

Investment Risk:
Investing in securities, including US equities and ETFs, involves inherent risks including the potential loss of principal. All investments are subject to market fluctuations, economic conditions, regulatory changes, and other factors that may affect their value. Past performance is not indicative of future results. This analysis is provided for informational and educational purposes only and should not be construed as investment advice under any circumstances.

No Investment Recommendation:
This analysis does not constitute, nor should it be interpreted as, an offer, solicitation, or recommendation to buy, sell, or hold any securities or financial products. Investors are strongly advised to conduct their own independent research and due diligence and to consult with a licensed financial advisor or an SEC-registered investment adviser before making any investment decisions, taking into account their individual financial situation, risk tolerance, and investment objectives.

Not SEC-Registered:
Finmagine is not registered as an investment adviser with the U.S. Securities and Exchange Commission (SEC) or any state securities authority. Nothing on this platform constitutes investment advice as defined under the Investment Advisers Act of 1940.

Conflict of Interest Disclosure:
The author and/or analyst may currently hold or have previously held positions in the securities discussed. Any such positions are not intended to influence the objectivity or independence of the analysis. This research is produced independently and is not sponsored, endorsed, or commissioned by any company or institution.

Information Sources:
The analysis is based on publicly available information including SEC filings (10-K, 10-Q), annual reports, management commentary, and publicly available financial data. Information is believed to be accurate as of the date of publication but may be subject to change without notice. Readers are encouraged to independently verify all information before acting upon it.

Forward-Looking Statements:
This analysis may contain forward-looking statements, forecasts, or projections that are inherently subject to risks, uncertainties, and assumptions. Actual results may differ materially from those expressed or implied. Finmagine does not undertake any obligation to update such statements in the future.

Limitation of Liability:
The content is provided "as is" without any warranties, express or implied. Finmagine expressly disclaims any liability for errors, omissions, or any losses incurred as a result of reliance on the information provided. Readers assume full responsibility for their investment decisions.